Literature DB >> 21877149

[76-year old patient with suspected but not confirmed "idiopathic myelofibrosis"].

C Feld1, H Spangenberger, J Böhm, D Meuthen, I Meuthen.   

Abstract

A 76-year old patient was referred to our Oncology Unit due to hepatosplenomegaly, anemia, thrombocytopenia, eosinophilia, elevation of lactat dehydrogenase and leucocytosis with occurrence of myeloid and erythroid precursors in the peripheral blood. Histopathological examination of the bone marrow and molecular genetics showing a c-kit-D816V-mutation confirmed the diagnosis of systemic mastocytosis without evidence of idiopathic myelofibrosis. After starting of prednisone treatment anemia, thromocytopenia and the patient's performance status rapidly improved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21877149     DOI： 10.1007/s00108-011-2812-9

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


  8 in total

Review 1.  Systemic mast cell disease: a review of the literature with special focus on the gastrointestinal manifestations.

Authors:  S Debeuckelaere; D F Schoors; G Devis
Journal:  Acta Clin Belg       Date:  1991       Impact factor: 1.264

2.  Systemic mastocytosis. Extracutaneous manifestations.

Authors:  R D Brunning; R W McKenna; J Rosai; J L Parkin; R Risdall
Journal:  Am J Surg Pathol       Date:  1983-07       Impact factor: 6.394

3.  Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD).

Authors:  Karl Sotlar; Sema Colak; Anja Bache; Sabina Berezowska; Manuela Krokowski; Burkhard Bültmann; Peter Valent; Hans-Peter Horny
Journal:  J Pathol       Date:  2010-04       Impact factor: 7.996

4.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Authors:  Jan Cools; Daniel J DeAngelo; Jason Gotlib; Elizabeth H Stover; Robert D Legare; Jorges Cortes; Jeffrey Kutok; Jennifer Clark; Ilene Galinsky; James D Griffin; Nicholas C P Cross; Ayalew Tefferi; James Malone; Rafeul Alam; Stanley L Schrier; Janet Schmid; Michal Rose; Peter Vandenberghe; Gregor Verhoef; Marc Boogaerts; Iwona Wlodarska; Hagop Kantarjian; Peter Marynen; Steven E Coutre; Richard Stone; D Gary Gilliland
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

5.  CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.

Authors:  Animesh Pardanani; Rhett P Ketterling; Stephanie R Brockman; Heather C Flynn; Sarah F Paternoster; Brandon M Shearer; Terra L Reeder; Chin-Yang Li; Nicholas C P Cross; Jan Cools; D Gary Gilliland; Gordon W Dewald; Ayalew Tefferi
Journal:  Blood       Date:  2003-07-03       Impact factor: 22.113

6.  Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.

Authors:  Karl Sotlar; Anja Bache; Florian Stellmacher; Burkhard Bültmann; Peter Valent; Hans-Peter Horny
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568

7.  Imatinib for systemic mast-cell disease.

Authors:  A Pardanani; M Elliott; T Reeder; C Y Li; E J Baxter; N C P Cross; A Tefferi
Journal:  Lancet       Date:  2003-08-16       Impact factor: 79.321

Review 8.  Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.

Authors:  Ayalew Tefferi; Radek Skoda; James W Vardiman
Journal:  Nat Rev Clin Oncol       Date:  2009-10-06       Impact factor: 66.675
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.